ORTHOPEDIATRICS CORP.

(KIDS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ORTHOPEDIATRICS CORP : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/10/2022 | 10:02am EDT

Item 2.02. Results of Operations and Financial Condition.

On January 10, 2022, OrthoPediatrics Corp. (the "Company") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021 and providing a related business update. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The financial information set forth in this Form 8-K reflects the Company's current preliminary revenue estimates, is subject to the completion of its audit process, and is subject to change. The Company's fourth quarter and full year ended December 31, 2021 results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. You should refer to the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 11, 2021, as updated and supplemented by our other SEC reports filed from time to time, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, you are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.2 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.2, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

  (d)   Exhibits
        Exhibit No.         Description
               99.1           Press release dated January 10, 2022 issued by OrthoPediatrics Corp.
               99.2           Orthopediatrics Corp. Investor Presentation dated January 2022
                104         Cover Page Interactive Data File (embedded within the Inline XBRL
                            document).


                                  * * * * * *

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ORTHOPEDIATRICS CORP.
05/10ORTHOPEDIATRICS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
05/10OrthoPediatrics Corp. Continues Double Diamond Sponsorship for 2022 POSNA Meeting
GL
05/10OrthoPediatrics Corp. Continues Double Diamond Sponsorship for 2022 POSNA Meeting
AQ
05/06Piper Sandler Adjusts OrthoPediatrics' Price Target to $55 From $80, Reiterates Overwei..
MT
05/05ORTHOPEDIATRICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
05/05Needham Adjusts Price Target for OrthoPediatrics to $59 From $65, Maintains Buy Rating
MT
05/05TRANSCRIPT : OrthoPediatrics Corp., Q1 2022 Earnings Call, May 05, 2022
CI
05/04ORTHOPEDIATRICS : Q1 Earnings Snapshot
AQ
05/04Earnings Flash (KIDS) ORTHOPEDIATRICS Posts Q1 Revenue $23.4M, vs. Street Est of $22.8M
MT
05/04OrthoPediatrics Corp. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
More news
Analyst Recommendations on ORTHOPEDIATRICS CORP.
More recommendations